載入中
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
一般交易時段
US$6.55
+US$0.385 · +6.24%
盤中時間採用ET。市場資料可能有所延遲。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日內區間
目前US$6.55
52週區間
目前US$6.55
盤中時間採用ET。市場資料可能有所延遲。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日內區間
目前US$6.55
52週區間
目前US$6.55
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 6808.8萬 USD | — | — | — | 47.9萬 USD |
| 毛利 | −6808.8萬 USD | — | — | — | −47.9萬 USD |
| 研究與開發 | 1750萬 USD | 7068.2萬 USD | 9379萬 USD | 6146.4萬 USD | 4279.4萬 USD |
| 銷售、一般及管理費用 | 1667.8萬 USD | 2609.3萬 USD | 3330.4萬 USD | 3255.2萬 USD | 2122.8萬 USD |
| 營業費用 | 3417.8萬 USD | 1.01億 USD | 1.25億 USD | 1.04億 USD | 6354.3萬 USD |
| 利息收入 | — | 396.2萬 USD | 763.7萬 USD | 321.6萬 USD | 33.7萬 USD |
| 利息支出 | — | — | — | 2431.6萬 USD | 3000 USD |
| 折舊和攤銷 | 97.2萬 USD | 97萬 USD | 96.9萬 USD | 84.5萬 USD | 47.9萬 USD |
| 營業利益 | −1.02億 USD | −1.01億 USD | −1.25億 USD | −1.04億 USD | −6402.2萬 USD |
| 淨利 | −1.06億 USD | −9694萬 USD | −1.18億 USD | −9563.9萬 USD | −5485.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI145.14萬0.00%2.3兆 USD0.03%US$381.51-0.02%
Simplify Propel Opportunities ETFSURI92.03萬1.22%7606.44萬 USD2.82%US$17.25650.00%
Vanguard Extended Market ETFVXF65.25萬0.00%954億 USD0.05%US$232.67-0.36%
iShares Micro-Cap ETFIWC12.58萬0.01%13.17億 USD0.60%US$180.18-0.81%
U.S. Micro Cap Portfolio ETFDFMC2.17萬0.00%75.44億 USD0.43%US$57.77+0.12%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR2.09萬0.00%455.76億 USD0.17%US$84.50+0.08%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9579.50.00%61.96億 USD0.26%US$68.525+0.30%
Dimensional - US Core Equity 2 ETFDFAC60260.00%885.59億 USD0.21%US$45.375+0.14%Vanguard Morningstar Total Stock Market ETFVTISimplify Propel Opportunities ETFSURIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
